ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase‐tyrosine kinase inhibitors currently approved for use in EML4‐ALK+ NSCLC include crizotinib (first generation), ceritinib, alectinib and brigatinib (second generation) and lastly, lorlatinib (third generation; Table 1).